Lion is focusing on strengthening its Oral Health Care segment as a top priority with an 8% annual growth target, emphasizing high-margin products to improve revenue and margins. The company has a track record of lifting dividends by approximately 12% per year on average over the past 10 years.
Cyborg Score Rationale
The company reported strong FY2025 results with sales of ¥422,092 million and net income of ¥27,587 million. Earnings per share have grown 8.4% on average over the last five years, demonstrating consistent performance. Risk factors include potential underperformance in overseas expansion and slower-than-expected margin improvement from oral care transitions.
Top Insights
Oral Health Care segment is a top strategic priority with 8% annual growth targets
Market capitalization stands at ¥394.67B (approximately $3.2B USD)
Conservative payout ratio at 44% of free cash flow, providing room for dividend growth
Significant overseas operations across Thailand, Taiwan, Singapore, Malaysia, Indonesia, Hong Kong, South Korea, and China
Named Competitors
Oral Care & Household Products — Global competitors in dental care, body wash, and cleaning products
Pharmaceutical & OTC Products — Japanese competitors in OTC medicines and health products
Recent Developments
(February 2026) FY2025 earnings announcement with ¥422B sales and board meeting on subsidiary transfers
(December 2025) Dividend of ¥15.00 per share announced with 10-year history of 12% annual growth
(January 2026) Stock trading at ¥1,452, down 0.65% in prior 24 hours with stable 3% weekly volatility
Open the full interactive Lion Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.